Company intelligence / Profile preview

Vyluma

Bridgewater, New Jersey, United Statesvyluma.com ↗

Ownership: Private
Development stage: NDA

Overview

Vyluma's lead compound NVK002 (low dose atropine 0.01%) completed Phase III CHAMP clinical study with positive results after four years of treatment and follow-up, showing continued strong safety, absence of rebound upon washout, and continued efficacy for treating myopia in children. FDA decision expected in January 2024.[5]

Therapeutic areas: Ophthalmology
Modalities: Pharmaceutical eye dropstopical treatments
Industry: Biotech

Drug pipeline

5 assets

NVK002

4 more assets in the full pipeline.

Request access →

Partnerships

Zhaoke Ophthalmology (China and South East Asia)Laboratories Théa (Europe)

Beyond the preview

Go deeper on Vyluma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vyluma.

Explore the full profile